Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury

Intensive Care Medicine

Volumn 36, Issue 1, 2010, Pages 157-163

  Sapru, Anil ^a   Curley, Martha A Q ^b   Brady, Sandra ^a   Matthay, Michael A ^a,c   Flori, Heidi ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Accurate respiratory distress syndrome; Acute lung injury; Clinical studies; Pediatrics; Plasminogen activator inhibitor 1 (PAI 1)

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ACUTE LUNG INJURY; ADULT; AGE DISTRIBUTION; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD LEVEL; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN; PEDIATRICS; PLASMINOGEN ACTIVATOR INHIBITOR 1 BLOOD LEVEL; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME; VENTILATOR;

ACUTE LUNG INJURY; CHILD; CHILD, PRESCHOOL; FEMALE; FIBRIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; PULMONARY ALVEOLI; RESPIRATORY DISTRESS SYNDROME, ADULT; SURVIVAL RATE; TREATMENT FAILURE;

EID: 76549118187     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-009-1690-2     Document Type: Article

References (31)

1. LB Ware MA Matthay 2000 The acute respiratory distress syndrome N Engl J Med 342 1334 1349 10.1056/NEJM200005043421806 1:STN:280:DC%2BD3c3jvFGhsw%3D%3D 10793167 (Pubitemid 30408719)
2. MA Curley PL Hibberd LD Fineman D Wypij MC Shih JE Thompson MJ Grant FE Barr NZ Cvijanovich L Sorce PM Luckett MA Matthay JH Arnold 2005 Effect of prone positioning on clinical outcomes in children with acute lung injury: a randomized controlled trial JAMA 294 229 237 10.1001/jama.294.2.229 1:CAS:528:DC%2BD2MXmtlSlt70%3D 16014597 (Pubitemid 41043793)
3. P Dahlem WM van Aalderen AP Bos 2007 Pediatric acute lung injury Paediatr Respir Rev 8 348 362 10.1016/j.prrv.2007.03.001 1:STN:280: DC%2BD2snotVGhtg%3D%3D 18005903 (Pubitemid 350102999)
4. HR Flori DV Glidden GW Rutherford MA Matthay 2005 Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality Am J Respir Crit Care Med 171 995 1001 10.1164/rccm.200404-544OC 15618461 (Pubitemid 40616948)
5. MC Kneyber AG Brouwers JA Caris S Chedamni FB Plotz 2008 Acute respiratory distress syndrome: is it underrecognized in the pediatric intensive care unit? Intensive Care Med 34 751 754 10.1007/s00134-008-1029-4 18288473
6. DF Willson NJ Thomas BP Markovitz LA Bauman JV DiCarlo S Pon BR Jacobs LS Jefferson MR Conaway EA Egan 2005 Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial JAMA 293 470 476 10.1001/jama.293.4.470 1:CAS:528:DC%2BD2MXntFKmtw%3D%3D 15671432
7. AG Randolph 2009 Management of acute lung injury and acute respiratory distress syndrome in children Crit Care Med 37 2448 2454 10.1097/CCM. 0b013e3181be7b72 19531940
8. JJ Zimmerman SR Akhtar E Caldwell GD Rubenfeld 2009 Incidence and outcomes of pediatric acute lung injury Pediatrics 124 87 95 10.1542/peds.2007-2462 19564287
9. LB Ware MA Matthay PE Parsons BT Thompson JL Januzzi MD Eisner 2007 Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome Crit Care Med 35 1821 1828 10.1097/01.CCM.0000221922.08878.49 17667242 (Pubitemid 47220354)
10. P Bertozzi B Astedt L Zenzius K Lynch F LeMaire W Zapol HA Chapman Jr 1990 Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome N Engl J Med 322 890 897 1:STN:280: DyaK3c7ptVOlug%3D%3D 2314423
11. RM Determann JL Millo CS Garrard MJ Schultz 2006 Bronchoalveolar levels of plasminogen activator inhibitor-1 and soluble tissue factor are sensitive and specific markers of pulmonary inflammation Intensive Care Med 32 946 947 10.1007/s00134-006-0167-9 1:CAS:528:DC%2BD1cXhtVOkur%2FP 16614807 (Pubitemid 43781389)
12. AA El Solh M Bhora L Pineda A Aquilina L Abbetessa E Berbary 2006 Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis Intensive Care Med 32 110 115 10.1007/s00134-005-2847-2 16284739 (Pubitemid 43039384)
13. S Idell KK James EG Levin BS Schwartz N Manchanda RJ Maunder TR Martin J McLarty DS Fair 1989 Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome J Clin Invest 84 695 705 10.1172/JCI114217 1:STN:280:DyaL1MzktVyqsQ%3D%3D 2788176 (Pubitemid 19197006)
14. B Nakstad T Lyberg OH Skjonsberg NP Boye 1990 Local activation of the coagulation and fibrinolysis systems in lung disease Thromb Res 57 827 838 10.1016/0049-3848(90)90150-B 1:STN:280:DyaK3czktF2qtg%3D%3D 2382254 (Pubitemid 20148998)
15. +-ATPase Am J Respir Cell Mol Biol 33 343 354 10.1165/rcmb.2004-0407OC 1:CAS:528:DC%2BD2MXhtV2hu7jL 16014898 (Pubitemid 41416284)
16. P Prabhakaran LB Ware KE White MT Cross MA Matthay MA Olman 2003 Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury Am J Physiol Lung Cell Mol Physiol 285 L20 L28 1:CAS:528:DC%2BD3sXls1Wmsb8%3D 12730079
17. GR Bernard A Artigas KL Brigham J Carlet K Falke L Hudson M Lamy JR Legall A Morris R Spragg 1994 The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination Am J Respir Crit Care Med 149 818 824 1:STN:280: DyaK2c7mtlCnsA%3D%3D 7509706 (Pubitemid 24082248)
18. IM Lang JJ Marsh MA Olman KM Moser RR Schleef 1994 Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli Circulation 90 706 712 1:STN:280:DyaK2czitVantg%3D%3D 8044939
19. D Schoenfeld 2002 Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome Crit Care Med 30 1772 1777 10.1097/00003246-200208000-00016 12163791
20. HA Chapman CL Allen OL Stone 1986 Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease Am Rev Respir Dis 133 437 443 1:STN:280:DyaL287lslWgtQ%3D%3D 3954252
21. G Choi MJ Schultz JW van Till P Bresser JS van der Zee MA Boermeester M Levi T van der Poll 2004 Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection Eur Respir J 24 786 789 10.1183/09031936.04. 00140703 1:STN:280:DC%2BD2crksV2qsQ%3D%3D 15516673 (Pubitemid 39504432)
22. A Gunther P Mosavi S Heinemann C Ruppert H Muth P Markart F Grimminger D Walmrath B Temmesfeld-Wollbruck W Seeger 2000 Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome Am J Respir Crit Care Med 161 454 462 1:STN:280:DC%2BD3c7otVamtg%3D%3D 10673185
23. Olman MA WL, Simmons WL, White KE, Matthay MA (2001) Pulmonary edema fluid levels of type 1 plasminogen activator inhibitor (PAI-1) predict a poor prognosis in clinical acute lung injury. Am J Respir Crit Care Med 163
24. MJ Schultz J Millo M Levi CE Hack GJ Weverling CS Garrard T van der Poll 2004 Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia Thorax 59 130 135 10.1136/thorax.2003. 013888 1:STN:280:DC%2BD2c%2FnvFWjsA%3D%3D 14760153 (Pubitemid 38223484)
25. Y Song SV Lynch J Flanagan H Zhuo W Tom RH Dotson MS Baek A Rubio-Mills G Singh E Kipnis D Glidden R Brown O Garcia JP Wiener-Kronish 2007 Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage fluids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa Anesthesiology 106 252 261 10.1097/00000542-200702000- 00012 1:CAS:528:DC%2BD2sXhtVKks7w%3D 17264718 (Pubitemid 46185169)
26. LB Ware M Eisner N Wickersham MA Olman B Thompson P Parsons MA Matthay 2004 Plasminogen activator inhibitor-1 (PAI-1), a marker of impaired fibrinolysis, is associated with higher mortality in patients with ALI/ARDS Am J Respir Crit Care Med 169 A115
27. T Hoekstra JM Geleijnse EG Schouten C Kluft 2004 Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk Thromb Haemost 91 861 872 1:CAS:528:DC%2BD2cXkt1ehsLo%3D 15116245
28. AJ Horrevoets 2004 Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance Br J Haematol 125 12 23 10.1111/j.1365-2141. 2004.04844.x 1:CAS:528:DC%2BD2cXjsFOnsLw%3D 15015963 (Pubitemid 38453272)
29. MR Gyetko GH Chen RA McDonald R Goodman GB Huffnagle CC Wilkinson JA Fuller GB Toews 1996 Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model J Clin Invest 97 1818 1826 10.1172/JCI118611 1:CAS:528:DyaK28XisFegs74%3D 8621764
30. RG Sitrin SB Shollenberger RM Strieter MR Gyetko 1996 Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes J Leukoc Biol 59 302 311 1:CAS:528:DyaK28XhtlKnsro%3D 8604004
31. RG Sitrin RF Todd III E Albrecht MR Gyetko 1996 The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes J Clin Invest 97 1942 1951 10.1172/JCI118626 1:CAS:528:DyaK28XisFegsLs%3D 8621779